Arsenic trioxide inhibits growth of human T‐cell leukaemia virus type I infected T‐cell lines more effectively than retinoic acids

Adult T‐cell leukaemia (ATL) is difficult to cure using conventional therapies. Recently the therapeutic possibility of retinoic acids (RA) has been reported. In this study, suppression of in vitro growth of human T‐cell leukaemia virus type I (HTLV‐I) infected T‐cell lines and fresh ATL cells by ar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 1998-12, Vol.103 (3), p.721-728
Hauptverfasser: Ishitsuka, Kenji, Hanada, Shuichi, Suzuki, Shinsuke, Utsunomiya, Atae, Chyuman, Yoshiko, Takeuchi, Syogo, Takeshita, Taketsugu, Shimotakahara, Sigemi, Uozumi, Kimiharu, Makino, Torahiko, Arima, Terukatsu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 728
container_issue 3
container_start_page 721
container_title British journal of haematology
container_volume 103
creator Ishitsuka, Kenji
Hanada, Shuichi
Suzuki, Shinsuke
Utsunomiya, Atae
Chyuman, Yoshiko
Takeuchi, Syogo
Takeshita, Taketsugu
Shimotakahara, Sigemi
Uozumi, Kimiharu
Makino, Torahiko
Arima, Terukatsu
description Adult T‐cell leukaemia (ATL) is difficult to cure using conventional therapies. Recently the therapeutic possibility of retinoic acids (RA) has been reported. In this study, suppression of in vitro growth of human T‐cell leukaemia virus type I (HTLV‐I) infected T‐cell lines and fresh ATL cells by arsenic trioxide (As2O3) were evaluated by comparison with a series of RA derivatives. Proliferation of four HTLV‐I‐infected T‐cell lines was significantly reduced within 72 h by 1.0 μmol/l As2O3. Growth of two out of four HTLV‐I‐infected T‐cell lines was also inhibited by 1.0 μmol/l RA, but to a lesser extent than by As2O3. The mechanism of this growth inhibition was due to the induction of apoptosis. Apoptosis was also induced in fresh ATL cells from patients by As2O3, but far less by RA. As described in patients with acute promyelocytic leukaemia, 1.0 μmol/l of As2O3 can be safely achieved in the serum of patients; however, it is difficult to maintain this concentration of RA. In conclusion, As2O3 has therapeutic potential for the treatment of ATL and may be far more clinically beneficial than RA.
doi_str_mv 10.1046/j.1365-2141.1998.01068.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69083357</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69083357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4708-22f357bc204bea7863c356aced7ef39c2af7e385f039031a95ce0b56727432163</originalsourceid><addsrcrecordid>eNqNkb1uFDEUhS0ECkvgEZAshOhmuLbnxy4okghIUCSaUFsezzXrZX4WeybZ7aioeUaeBA-7CoiKypbOd8699iGEMsgZFNXrTc5EVWacFSxnSskcGFQy3z0gq3vhIVkBQJ0lg3xMnsS4AWACSnZCTpQsJediRb6fhYiDt3QKftz5Fqkf1r7xU6Sfw3g3reno6HruzUBvfn77YbHraIfzF4O9N_TWhznSab9FepWMDu2E7V-gHzDSfgxI0S2iv8VuT6d1Sgs4-WFMg431bXxKHjnTRXx2PE_Jp3dvby4us-uP768uzq4zW9QgM86dKOvGcigaNLWshBVlZSy2NTqhLDeuRiFLB0KBYEaVFqEpq5rXheCsEqfk1SF3G8avM8ZJ9z4uu5oBxznqSoEUaUQCX_wDbsY5DGk3zdLnKaWAJ0geIBvGGAM6vQ2-N2GvGeilJ73RSx16qUMvPenfPeldsj4_5s9Nj-298VhM0l8edROt6Vwwg_XxT34pK-DLe94csDvf4f6_x-vzD5fLTfwC_uywjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198599902</pqid></control><display><type>article</type><title>Arsenic trioxide inhibits growth of human T‐cell leukaemia virus type I infected T‐cell lines more effectively than retinoic acids</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><creator>Ishitsuka, Kenji ; Hanada, Shuichi ; Suzuki, Shinsuke ; Utsunomiya, Atae ; Chyuman, Yoshiko ; Takeuchi, Syogo ; Takeshita, Taketsugu ; Shimotakahara, Sigemi ; Uozumi, Kimiharu ; Makino, Torahiko ; Arima, Terukatsu</creator><creatorcontrib>Ishitsuka, Kenji ; Hanada, Shuichi ; Suzuki, Shinsuke ; Utsunomiya, Atae ; Chyuman, Yoshiko ; Takeuchi, Syogo ; Takeshita, Taketsugu ; Shimotakahara, Sigemi ; Uozumi, Kimiharu ; Makino, Torahiko ; Arima, Terukatsu</creatorcontrib><description>Adult T‐cell leukaemia (ATL) is difficult to cure using conventional therapies. Recently the therapeutic possibility of retinoic acids (RA) has been reported. In this study, suppression of in vitro growth of human T‐cell leukaemia virus type I (HTLV‐I) infected T‐cell lines and fresh ATL cells by arsenic trioxide (As2O3) were evaluated by comparison with a series of RA derivatives. Proliferation of four HTLV‐I‐infected T‐cell lines was significantly reduced within 72 h by 1.0 μmol/l As2O3. Growth of two out of four HTLV‐I‐infected T‐cell lines was also inhibited by 1.0 μmol/l RA, but to a lesser extent than by As2O3. The mechanism of this growth inhibition was due to the induction of apoptosis. Apoptosis was also induced in fresh ATL cells from patients by As2O3, but far less by RA. As described in patients with acute promyelocytic leukaemia, 1.0 μmol/l of As2O3 can be safely achieved in the serum of patients; however, it is difficult to maintain this concentration of RA. In conclusion, As2O3 has therapeutic potential for the treatment of ATL and may be far more clinically beneficial than RA.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1046/j.1365-2141.1998.01068.x</identifier><identifier>PMID: 9858223</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, U.K. and Cambridge, USA: Blackwell Science Ltd</publisher><subject>adult T‐cell leukaemia ; AIDS/HIV ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; apoptosis ; Apoptosis - drug effects ; Arsenic Trioxide ; Arsenicals - therapeutic use ; Biological and medical sciences ; Cell Division ; General aspects ; growth inhibition ; Hematology ; HTLV-I Infections - drug therapy ; HTLV-I Infections - pathology ; HTLV-I Infections - virology ; Human T-lymphotropic virus 1 - growth &amp; development ; Humans ; Medical sciences ; Oxides - therapeutic use ; Pharmacology. Drug treatments ; retinoic acid ; T-Lymphocytes - pathology ; T-Lymphocytes - virology ; Tretinoin - therapeutic use ; Tumor Cells, Cultured</subject><ispartof>British journal of haematology, 1998-12, Vol.103 (3), p.721-728</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Dec 1998</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4708-22f357bc204bea7863c356aced7ef39c2af7e385f039031a95ce0b56727432163</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2141.1998.01068.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2141.1998.01068.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,1428,27905,27906,45555,45556,46390,46814</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1586026$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9858223$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishitsuka, Kenji</creatorcontrib><creatorcontrib>Hanada, Shuichi</creatorcontrib><creatorcontrib>Suzuki, Shinsuke</creatorcontrib><creatorcontrib>Utsunomiya, Atae</creatorcontrib><creatorcontrib>Chyuman, Yoshiko</creatorcontrib><creatorcontrib>Takeuchi, Syogo</creatorcontrib><creatorcontrib>Takeshita, Taketsugu</creatorcontrib><creatorcontrib>Shimotakahara, Sigemi</creatorcontrib><creatorcontrib>Uozumi, Kimiharu</creatorcontrib><creatorcontrib>Makino, Torahiko</creatorcontrib><creatorcontrib>Arima, Terukatsu</creatorcontrib><title>Arsenic trioxide inhibits growth of human T‐cell leukaemia virus type I infected T‐cell lines more effectively than retinoic acids</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Adult T‐cell leukaemia (ATL) is difficult to cure using conventional therapies. Recently the therapeutic possibility of retinoic acids (RA) has been reported. In this study, suppression of in vitro growth of human T‐cell leukaemia virus type I (HTLV‐I) infected T‐cell lines and fresh ATL cells by arsenic trioxide (As2O3) were evaluated by comparison with a series of RA derivatives. Proliferation of four HTLV‐I‐infected T‐cell lines was significantly reduced within 72 h by 1.0 μmol/l As2O3. Growth of two out of four HTLV‐I‐infected T‐cell lines was also inhibited by 1.0 μmol/l RA, but to a lesser extent than by As2O3. The mechanism of this growth inhibition was due to the induction of apoptosis. Apoptosis was also induced in fresh ATL cells from patients by As2O3, but far less by RA. As described in patients with acute promyelocytic leukaemia, 1.0 μmol/l of As2O3 can be safely achieved in the serum of patients; however, it is difficult to maintain this concentration of RA. In conclusion, As2O3 has therapeutic potential for the treatment of ATL and may be far more clinically beneficial than RA.</description><subject>adult T‐cell leukaemia</subject><subject>AIDS/HIV</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Arsenic Trioxide</subject><subject>Arsenicals - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cell Division</subject><subject>General aspects</subject><subject>growth inhibition</subject><subject>Hematology</subject><subject>HTLV-I Infections - drug therapy</subject><subject>HTLV-I Infections - pathology</subject><subject>HTLV-I Infections - virology</subject><subject>Human T-lymphotropic virus 1 - growth &amp; development</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Oxides - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>retinoic acid</subject><subject>T-Lymphocytes - pathology</subject><subject>T-Lymphocytes - virology</subject><subject>Tretinoin - therapeutic use</subject><subject>Tumor Cells, Cultured</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkb1uFDEUhS0ECkvgEZAshOhmuLbnxy4okghIUCSaUFsezzXrZX4WeybZ7aioeUaeBA-7CoiKypbOd8699iGEMsgZFNXrTc5EVWacFSxnSskcGFQy3z0gq3vhIVkBQJ0lg3xMnsS4AWACSnZCTpQsJediRb6fhYiDt3QKftz5Fqkf1r7xU6Sfw3g3reno6HruzUBvfn77YbHraIfzF4O9N_TWhznSab9FepWMDu2E7V-gHzDSfgxI0S2iv8VuT6d1Sgs4-WFMg431bXxKHjnTRXx2PE_Jp3dvby4us-uP768uzq4zW9QgM86dKOvGcigaNLWshBVlZSy2NTqhLDeuRiFLB0KBYEaVFqEpq5rXheCsEqfk1SF3G8avM8ZJ9z4uu5oBxznqSoEUaUQCX_wDbsY5DGk3zdLnKaWAJ0geIBvGGAM6vQ2-N2GvGeilJ73RSx16qUMvPenfPeldsj4_5s9Nj-298VhM0l8edROt6Vwwg_XxT34pK-DLe94csDvf4f6_x-vzD5fLTfwC_uywjQ</recordid><startdate>199812</startdate><enddate>199812</enddate><creator>Ishitsuka, Kenji</creator><creator>Hanada, Shuichi</creator><creator>Suzuki, Shinsuke</creator><creator>Utsunomiya, Atae</creator><creator>Chyuman, Yoshiko</creator><creator>Takeuchi, Syogo</creator><creator>Takeshita, Taketsugu</creator><creator>Shimotakahara, Sigemi</creator><creator>Uozumi, Kimiharu</creator><creator>Makino, Torahiko</creator><creator>Arima, Terukatsu</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Blackwell Publishing Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>199812</creationdate><title>Arsenic trioxide inhibits growth of human T‐cell leukaemia virus type I infected T‐cell lines more effectively than retinoic acids</title><author>Ishitsuka, Kenji ; Hanada, Shuichi ; Suzuki, Shinsuke ; Utsunomiya, Atae ; Chyuman, Yoshiko ; Takeuchi, Syogo ; Takeshita, Taketsugu ; Shimotakahara, Sigemi ; Uozumi, Kimiharu ; Makino, Torahiko ; Arima, Terukatsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4708-22f357bc204bea7863c356aced7ef39c2af7e385f039031a95ce0b56727432163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>adult T‐cell leukaemia</topic><topic>AIDS/HIV</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Arsenic Trioxide</topic><topic>Arsenicals - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cell Division</topic><topic>General aspects</topic><topic>growth inhibition</topic><topic>Hematology</topic><topic>HTLV-I Infections - drug therapy</topic><topic>HTLV-I Infections - pathology</topic><topic>HTLV-I Infections - virology</topic><topic>Human T-lymphotropic virus 1 - growth &amp; development</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Oxides - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>retinoic acid</topic><topic>T-Lymphocytes - pathology</topic><topic>T-Lymphocytes - virology</topic><topic>Tretinoin - therapeutic use</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishitsuka, Kenji</creatorcontrib><creatorcontrib>Hanada, Shuichi</creatorcontrib><creatorcontrib>Suzuki, Shinsuke</creatorcontrib><creatorcontrib>Utsunomiya, Atae</creatorcontrib><creatorcontrib>Chyuman, Yoshiko</creatorcontrib><creatorcontrib>Takeuchi, Syogo</creatorcontrib><creatorcontrib>Takeshita, Taketsugu</creatorcontrib><creatorcontrib>Shimotakahara, Sigemi</creatorcontrib><creatorcontrib>Uozumi, Kimiharu</creatorcontrib><creatorcontrib>Makino, Torahiko</creatorcontrib><creatorcontrib>Arima, Terukatsu</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishitsuka, Kenji</au><au>Hanada, Shuichi</au><au>Suzuki, Shinsuke</au><au>Utsunomiya, Atae</au><au>Chyuman, Yoshiko</au><au>Takeuchi, Syogo</au><au>Takeshita, Taketsugu</au><au>Shimotakahara, Sigemi</au><au>Uozumi, Kimiharu</au><au>Makino, Torahiko</au><au>Arima, Terukatsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Arsenic trioxide inhibits growth of human T‐cell leukaemia virus type I infected T‐cell lines more effectively than retinoic acids</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>1998-12</date><risdate>1998</risdate><volume>103</volume><issue>3</issue><spage>721</spage><epage>728</epage><pages>721-728</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Adult T‐cell leukaemia (ATL) is difficult to cure using conventional therapies. Recently the therapeutic possibility of retinoic acids (RA) has been reported. In this study, suppression of in vitro growth of human T‐cell leukaemia virus type I (HTLV‐I) infected T‐cell lines and fresh ATL cells by arsenic trioxide (As2O3) were evaluated by comparison with a series of RA derivatives. Proliferation of four HTLV‐I‐infected T‐cell lines was significantly reduced within 72 h by 1.0 μmol/l As2O3. Growth of two out of four HTLV‐I‐infected T‐cell lines was also inhibited by 1.0 μmol/l RA, but to a lesser extent than by As2O3. The mechanism of this growth inhibition was due to the induction of apoptosis. Apoptosis was also induced in fresh ATL cells from patients by As2O3, but far less by RA. As described in patients with acute promyelocytic leukaemia, 1.0 μmol/l of As2O3 can be safely achieved in the serum of patients; however, it is difficult to maintain this concentration of RA. In conclusion, As2O3 has therapeutic potential for the treatment of ATL and may be far more clinically beneficial than RA.</abstract><cop>Oxford, U.K. and Cambridge, USA</cop><pub>Blackwell Science Ltd</pub><pmid>9858223</pmid><doi>10.1046/j.1365-2141.1998.01068.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1048
ispartof British journal of haematology, 1998-12, Vol.103 (3), p.721-728
issn 0007-1048
1365-2141
language eng
recordid cdi_proquest_miscellaneous_69083357
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content
subjects adult T‐cell leukaemia
AIDS/HIV
Antineoplastic agents
Antineoplastic Agents - therapeutic use
apoptosis
Apoptosis - drug effects
Arsenic Trioxide
Arsenicals - therapeutic use
Biological and medical sciences
Cell Division
General aspects
growth inhibition
Hematology
HTLV-I Infections - drug therapy
HTLV-I Infections - pathology
HTLV-I Infections - virology
Human T-lymphotropic virus 1 - growth & development
Humans
Medical sciences
Oxides - therapeutic use
Pharmacology. Drug treatments
retinoic acid
T-Lymphocytes - pathology
T-Lymphocytes - virology
Tretinoin - therapeutic use
Tumor Cells, Cultured
title Arsenic trioxide inhibits growth of human T‐cell leukaemia virus type I infected T‐cell lines more effectively than retinoic acids
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T18%3A53%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Arsenic%20trioxide%20inhibits%20growth%20of%20human%20T%E2%80%90cell%20leukaemia%20virus%20type%20I%20infected%20T%E2%80%90cell%20lines%20more%20effectively%20than%20retinoic%20acids&rft.jtitle=British%20journal%20of%20haematology&rft.au=Ishitsuka,%20Kenji&rft.date=1998-12&rft.volume=103&rft.issue=3&rft.spage=721&rft.epage=728&rft.pages=721-728&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1046/j.1365-2141.1998.01068.x&rft_dat=%3Cproquest_cross%3E69083357%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198599902&rft_id=info:pmid/9858223&rfr_iscdi=true